BELANTAMAB MAFODOTIN
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Blenrep®
- Form and strength:
-
- Powder for injection 70 mg (50 mg per ml)
- Powder for injection 100 mg (50 mg per ml)
- Submission sponsor:
- GLAXOSMITHKLINE AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Relapsed and/or refractory multiple myeloma (MM)
- Listing requested:
- Resubmission to request listing of belantamab mafodotin for use in combination with bortezomib and dexamethasone for the treatment of relapsed and/or refractory MM in patients who have progressive disease after at least one prior line of therapy. This item was previously considered by the PBAC at its November 2025 meeting.
- Funding program:
- PBS Section 100 (Efficient Funding of Chemotherapy)
- Request authority level:
- Authority Required (Telephone/Online)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1213
Page last updated
31 May 2026
v.9.19